Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Rituximab in Relapsed/Refractory Indolent B-Cell Lymphoma
NCT02049541Phase 1Completed
- Start
- Jul 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buparlisib in indolent B-cell lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL) and 3 more. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
indolent B-cell lymphomamantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02049541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049541.